ArticleAmerican journal of cancer research2011
Tumor-targeted RNA-interference: functional non-viral nanovectors.
Article in American journal of cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- 1,8-Naphthalimide-Based Multifunctional Compounds as CuFrontiers in chemistry · 2019Article
- A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Therapeutic potential of chemically modified siRNA: Recent trends.Chemical biology & drug design · 2017Review
- Nanoparticle ligand presentation for targeting solid tumors.AAPS PharmSciTech · 2014Review
- Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.Gastroenterology · 2014Article
- In vivo safety evaluation of polyarginine coated magnetic nanovectors.Molecular pharmaceutics · 2013Article
- Comparison of non-coding RNAs in human and canine cancer.Frontiers in genetics · 2013Article
- Lipid-based vectors for siRNA delivery.Journal of drug targeting · 2012Review
- In vivo gene delivery by nonviral vectors: overcoming hurdles?Molecular therapy : the journal of the American Society of Gene Therapy · 2012Review
- Function of chloride intracellular channel 1 in gastric cancer cells.World journal of gastroenterology · 2012Article
- Cancer stem cells and drug resistance: the potential of nanomedicine.Nanomedicine (London, England) · 2012Review
- Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules.Sensors (Basel, Switzerland) · 2012Review
- Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management.Pathology research international · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
While small interfering RNA (siRNA) and microRNA (miRNA) have attracted extensive attention and showed significant promise for the study, diagnosis and treatment of human cancers, delivering siRNA or miRNA specifically and efficiently into tumor cells in vivo remains a great challenge. Delivery barriers, which arise mainly from the routes of administration associated with complex physiochemical microenvironments of the human body and the unique properties of RNAs, hinder the development of RNA-interference (RNAi)-based therapeutics in clinical practice. However, in available delivery systems, non-viral nanoparticle-based gene/RNA-delivery vectors, or nanovectors, are showing powerful delivery capacities and huge potential for improvements in functional nanomaterials, including novel fabrication approaches which would greatly enhance delivery performance. In this review, we summarize the currently recognized RNAi delivery barriers and the anti-barrier requirements related to vectors' properties. Recent efforts and achievements in the development of novel nanomaterials, nanovectors fabrication methods, and delivery approaches are discussed. We also review the outstanding needs in the areas of material synthesis and assembly, multifunction combinations, proper delivery and assisting approaches that require more intensive investigation for the comprehensive and effective delivery of RNAi by non-viral nanovectors.
Indexed as
Identifiers
21572539PMC3092671W1601166484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.